Atlas
Back to RCM
Strategic Advisor·RCM

Mark Wise

Managing Director, Healthcare Technology & Services (revenue cycle management, payments, provider IT) at TripleTree

New York, NY, USA

MW
LinkedIn
Why they matter

Sits at the center of RCM and provider-tech deal flow at TripleTree, having recently banked Health Prime, Kodiak Solutions, and CPS — he knows which assets are coming to market.

Background

Mark Wise is a Managing Director at TripleTree, the healthcare-focused investment bank (now part of Capital One), covering software and tech-enabled services platforms serving provider, pharmacy, and payer end-markets — including revenue cycle management, payments, provider IT, and specialty pharmacy. He previously worked in healthcare M&A at Hammond Hanlon Camp and in healthcare investment banking at Morgan Keegan & Company, and began his career at Laffer Investments. He holds a B.A. in Economics and History from Vanderbilt University.

Notable deals

  • 2024
    Lead investment banker advising Health Prime International, an RCM solutions provider for physician practices, on its majority investment from Aquiline Capital Partners
  • 2023
    Lead investment banker advising TPG on its majority-stake acquisition of Crowe Healthcare Consulting, carved out and rebranded as Kodiak Solutions
  • 2024
    Lead investment banker on the sale of CPS, a pharmacy services and technology firm serving 800+ healthcare facilities, to an undisclosed buyer
  • 2019
    Lead investment banker advising on Starr Investment Holdings' ~$700 million investment in Radiology Partners, the largest US radiology practice

Call-prep brief

Background

  • Managing Director at TripleTree (healthcare investment bank acquired by Capital One in 2021), based in New York; roles span new business development, client engagement, and transaction execution.
  • Prior stints: Hammond Hanlon Camp (healthcare services M&A), Morgan Keegan healthcare IB, Laffer Investments. Vanderbilt economics/history grad.

Current focus

  • Software and tech-enabled services across provider, pharmacy, and payer end-markets: revenue cycle management, payments, provider IT, pharmacy software, specialty pharmacy, and infusion.

What they care about

  • Sell-side and sponsor relationships in mid-market healthcare IT; positioning platforms for sponsor-to-sponsor or strategic exits. His recent work shows a pattern of RCM and pharmacy-services carve-outs and recaps.

Recent moves

  • Feb 2024: advised Health Prime International on Aquiline's majority investment (physician-practice RCM).
  • Feb 2024: advised on the sale of CPS (pharmacy operations/technology, 800+ facilities).
  • Aug 2023: advised TPG on acquiring Crowe Healthcare Consulting, now Kodiak Solutions (net-revenue/RCM analytics).

Potential sensitivities

  • He is a banker, not an operator: expect him to filter conversations through mandate potential and confidentiality on live processes. Capital One ownership may add compliance formality.

Questions to ask

  1. Where is RCM buyer appetite strongest right now — full outsourcing, point solutions, or AI-native automation layers?
  2. What did the Health Prime and Kodiak processes reveal about sponsor valuation discipline in provider tech?
  3. Which sub-segments (payments, prior auth, specialty pharmacy tech) does he expect to come to market in the next 12–18 months?

Outreach draft

Subject
RCM deal landscape — quick call?
Hi Mark, I'm on the investment team at a private equity firm building a thesis in revenue cycle management and provider technology. Your recent work — Health Prime's recapitalization with Aquiline, TPG's carve-out of Kodiak Solutions, and the CPS sale — sits exactly where we're focused, and few bankers have seen that corner of the market as closely. Would you be open to a 30-minute call to compare notes on where RCM and pharmacy-services assets are heading? Happy to share our perspective on the space, and there may be natural ways to work together on future processes. Best regards, [Your Name]

Linked companies

Sources